Lexaria Bioscience Corp. (LEXX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Lexaria Bioscience reported revenue of $705,923, up 52.0% from $464,278 the year before. Net income was -$11.9M (a -1686.0% net margin), or -$9.90 per diluted share. Gross margin was 99.6% and operating margin was -1683.0%. Operating activities generated -$10.5M of cash, leaving -$10.5M of free cash flow. At fiscal year end, Lexaria Bioscience held $4.2M in total assets against $1.6M in total liabilities.
Open the full interactive Lexaria Bioscience financials → Quarterly statements, key ratios, valuation history and price charts.
Lexaria Bioscience Key Stats
| Share Price | $2.80 |
|---|---|
| Market Cap | $4.6M |
| Revenue YoY Growth | +52.0% |
| 52-Week Range | $2.77 – $20.10 |
| Shares Outstanding | 396,733 (basic, 2022 Q3) |
Lexaria Bioscience Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $384,543 | $722,738 | $255,397 | $226,208 | $464,278 | $705,923 |
| Cost of Goods Sold | $99,378 | $175,346 | $71,841 | $31,500 | $4,822 | $2,720 |
| Gross Profit | $285,165 | $547,392 | $183,556 | $194,708 | $459,456 | $703,203 |
| Operating Income | -$4.1M | -$5.7M | -$7.4M | -$6.5M | -$5.8M | -$11.9M |
| Pre-Tax Income | -$4.0M | -$4.2M | -$7.4M | -$6.7M | -$5.8M | -$11.9M |
| Income Tax | $2,319 | $6,093 | $0 | -$47,626 | -$13,309 | -$9,593 |
| Net Income | -$4.1M | -$4.2M | -$7.3M | -$6.7M | -$5.8M | -$11.9M |
| Diluted EPS | -$0.75 | -$14.25 | — | — | -$7.05 | -$9.90 |
Lexaria Bioscience Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $174,000 | $0 | $20,000 | $0 |
| Net Income | -$2.7M | -$1.6M | -$1.4M | -$2.0M |
| Diluted EPS | -$0.15 | -$1.05 | -$0.90 | -$1.20 |
Lexaria Bioscience Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.3M | $10.9M | $5.8M | — | — | — |
| Current Assets | $1.9M | $12.4M | $7.0M | $2.2M | $7.9M | $3.5M |
| Total Assets | $2.8M | $13.3M | $7.8M | $3.1M | $8.9M | $4.2M |
| Current Liabilities | $225,917 | $153,276 | $194,036 | $267,735 | $1.1M | $1.5M |
| Total Long-Term Debt | $30,670 | — | — | — | — | — |
| Total Liabilities | $345,980 | $203,265 | $201,437 | $403,908 | $1.2M | $1.6M |
| Shareholders' Equity | $2.5M | $13.1M | $7.9M | $3.0M | $8.0M | $3.0M |
Lexaria Bioscience Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$2.7M | -$4.0M | -$4.9M | -$5.9M | -$5.0M | -$10.5M |
| Cash From Investing | -$26,843 | $193,880 | -$180,640 | -$169,610 | -$188,605 | -$243,019 |
| Cash From Financing | $2.7M | $13.4M | -$44,600 | $1.6M | — | $6.0M |
| Free Cash Flow | -$2.7M | — | — | -$5.9M | -$5.0M | -$10.5M |
Figures from Lexaria Bioscience's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lexaria Bioscience financials page for every line item.
Lexaria Bioscience Company Profile
| Ticker | LEXX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Kelowna, British Columbia, Canada |
| Incorporated in | Nevada |
| Fiscal Year End | August 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001348362 |
Frequently Asked Questions
What was Lexaria Bioscience's revenue in fiscal 2025?
Lexaria Bioscience (LEXX) reported revenue of $705,923 for fiscal 2025.
What is Lexaria Bioscience's annual revenue history?
Lexaria Bioscience's annual revenue by fiscal year: 2020: $384,543; 2021: $722,738; 2022: $255,397; 2023: $226,208; 2024: $464,278; 2025: $705,923.
What was Lexaria Bioscience's net income in fiscal 2025?
Lexaria Bioscience reported net income of -$11.9M for fiscal 2025.
What was Lexaria Bioscience's earnings per share (EPS) in fiscal 2025?
Lexaria Bioscience's diluted EPS was -$9.90 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Lexaria Bioscience generate in fiscal 2025?
Lexaria Bioscience generated -$10.5M of free cash flow in fiscal 2025.
What was Lexaria Bioscience's revenue last quarter?
In its most recent reported quarter (2026 Q3), Lexaria Bioscience reported revenue of $0.
How many shares of Lexaria Bioscience are outstanding?
Lexaria Bioscience reported a weighted average of 396,733 basic shares outstanding in 2022 Q3.
What is Lexaria Bioscience's market cap?
Based on its latest closing price, Lexaria Bioscience (LEXX) has a market capitalization of about $4.6M.
When does Lexaria Bioscience's fiscal year end?
Lexaria Bioscience's fiscal year end, as registered with the SEC, is August 31.
Where is Lexaria Bioscience headquartered?
Lexaria Bioscience lists its business address in Kelowna, British Columbia, Canada in its SEC filings.